Since stimulation with IL-12 and IL-18 without simultaneous TCR stimulus induces potent anti-tumoral activity in γδ T cells comparable to that after TCR crosslinking i.e., efficient killing of tumor cells and driving cancer cells into senescence -, the use of IL-12/IL-18-stimulated γδ T cells is highly recommended for adoptive cell therapy to boost anti-tumor activity by γδ T cells. Here, IL18 is linked to cancer.